

# Jochen K Lennerz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8346532/publications.pdf>

Version: 2024-02-01

140  
papers

8,496  
citations

71061

41  
h-index

49868

87  
g-index

144  
all docs

144  
docs citations

144  
times ranked

14226  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i> -Rearranged Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 1118-1133.	7.7	919
2	COVID-19-neutralizing antibodies predict disease severity and survival. <i>Cell</i> , 2021, 184, 476-488.e11.	13.5	586
3	<i>MET</i> Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib. <i>Journal of Clinical Oncology</i> , 2011, 29, 4803-4810.	0.8	404
4	Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with <i>FGFR2</i> Fusion-Positive Cholangiocarcinoma. <i>Cancer Discovery</i> , 2017, 7, 252-263.	7.7	384
5	Origins of lymphatic and distant metastases in human colorectal cancer. <i>Science</i> , 2017, 357, 55-60.	6.0	358
6	Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i> -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> Fusion. <i>Cancer Discovery</i> , 2018, 8, 1529-1539.	7.7	342
7	H <sub>2</sub> S and NO cooperatively regulate vascular tone by activating a neuroendocrine HNO-TRPA1-CGRP signalling pathway. <i>Nature Communications</i> , 2014, 5, 4381.	5.8	324
8	Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: Differences between peripheral and central CGRP receptor distribution. <i>Journal of Comparative Neurology</i> , 2008, 507, 1277-1299.	0.9	287
9	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with <i>FGFR2</i> Fusion-Positive Intrahepatic Cholangiocarcinoma. <i>Cancer Discovery</i> , 2019, 9, 1064-1079.	7.7	254
10	Evaluation of SARS-CoV-2 serology assays reveals a range of test performance. <i>Nature Biotechnology</i> , 2020, 38, 1174-1183.	9.4	251
11	Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation. <i>Cancer Discovery</i> , 2021, 11, 1913-1922.	7.7	243
12	Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung Cancer. <i>Cancer Discovery</i> , 2018, 8, 714-729.	7.7	228
13	Transient receptor potential cation channel, subfamily C, member 5 (TRPC5) is a cold-transducer in the peripheral nervous system. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18114-18119.	3.3	192
14	A protein and mRNA expression-based classification of gastric cancer. <i>Modern Pathology</i> , 2016, 29, 772-784.	2.9	142
15	<i>MET</i> Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2535-2545.	3.2	127
16	Treatment with Next-Generation ALK Inhibitors Fuels Plasma <i>ALK</i> Mutation Diversity. <i>Clinical Cancer Research</i> , 2019, 25, 6662-6670.	3.2	122
17	Clinical sensitivity and interpretation of PCR and serological COVID-19 diagnostics for patients presenting to the hospital. <i>FASEB Journal</i> , 2020, 34, 13877-13884.	0.2	117
18	Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an <i>NTRK</i> Gene Fusion. <i>JCO Precision Oncology</i> , 2018, 2018, 1-12.	1.5	112

#	ARTICLE	IF	CITATIONS
19	Implementing the DICOM Standard for Digital Pathology. <i>Journal of Pathology Informatics</i> , 2018, 9, 37.	0.8	93
20	Classical pathology and mutational load of breast cancer – integration of two worlds. <i>Journal of Pathology: Clinical Research</i> , 2015, 1, 225-238.	1.3	91
21	Loss of ATM accelerates pancreatic cancer formation and epithelial–mesenchymal transition. <i>Nature Communications</i> , 2015, 6, 7677.	5.8	90
22	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2020, 6, 16.	2.3	90
23	ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non–Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 872-877.	0.5	87
24	Food Addiction, High-Glycemic-Index Carbohydrates, and Obesity. <i>Clinical Chemistry</i> , 2018, 64, 64-71.	1.5	87
25	Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNA. <i>JCO Precision Oncology</i> , 2018, 2018, 1-14.	1.5	86
26	Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm. <i>Oncotarget</i> , 2014, 5, 6404-6413.	0.8	82
27	Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 158-165.	3.2	81
28	Pan-cancer analysis of copy number changes in programmed death–ligand 1 (PD–L1, CD274) – associations with gene expression, mutational load, and survival. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 626-639.	1.5	80
29	Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 816-824.	0.5	78
30	Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR -Mutant Lung Cancer Harboring De Novo MET Amplification. <i>Journal of Thoracic Oncology</i> , 2016, 11, e83-e85.	0.5	75
31	Lymph node metastases develop through a wider evolutionary bottleneck than distant metastases. <i>Nature Genetics</i> , 2020, 52, 692-700.	9.4	75
32	High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts. <i>Journal of Infectious Diseases</i> , 2020, 222, 1955-1959.	1.9	72
33	Novel gene fusions in secretory carcinoma of the salivary glands: enlarging the ETV6 family. <i>Human Pathology</i> , 2019, 83, 50-58.	1.1	70
34	Clinicopathologic Characteristics of BRG1-Deficient NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 766-776.	0.5	68
35	Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 1877-1885.	3.2	67
36	Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5561-5571.	3.2	64

#	ARTICLE	IF	CITATIONS
37	Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1530-1538.	0.5	62
38	Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion-Positive Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2899-2909.	3.2	62
39	A diagnostic algorithm to distinguish desmoplastic from spindle cell melanoma. <i>Modern Pathology</i> , 2014, 27, 524-534.	2.9	61
40	Human and mouse trigeminal ganglia cell atlas implicates multiple cell types in migraine. <i>Neuron</i> , 2022, 110, 1806-1821.e8.	3.8	61
41	The Amount of Bifidobacterium Genus in Colorectal Carcinoma Tissue in Relation to Tumor Characteristics and Clinical Outcome. <i>American Journal of Pathology</i> , 2018, 188, 2839-2852.	1.9	51
42	Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1497-1506.	0.5	46
43	Cell-Free HPV DNA Provides an Accurate and Rapid Diagnosis of HPV-Associated Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 719-727.	3.2	46
44	<i>SOCS1</i> Mutation Subtypes Predict Divergent Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients. <i>Oncotarget</i> , 2013, 4, 35-47.	0.8	44
45	Odontoblast TRPC5 channels signal cold pain in teeth. <i>Science Advances</i> , 2021, 7, .	4.7	42
46	Recent advances in the histological and molecular classification of endometrial stromal neoplasms. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 665-678.	1.4	41
47	Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling. <i>Seminars in Cancer Biology</i> , 2022, 84, 129-143.	4.3	41
48	Genotype-targeted local therapy of glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8388-E8394.	3.3	40
49	Allelic Ratio of <i>KRAS</i> Mutations in Pancreatic Cancer. <i>Oncologist</i> , 2015, 20, e8-e9.	1.9	36
50	Small cell transformation of <i>ROS1</i> fusion-positive lung cancer resistant to <i>ROS1</i> inhibition. <i>Npj Precision Oncology</i> , 2020, 4, 21.	2.3	36
51	Association of <i>Fusobacterium nucleatum</i> with Specific T-cell Subsets in the Colorectal Carcinoma Microenvironment. <i>Clinical Cancer Research</i> , 2021, 27, 2816-2826.	3.2	36
52	A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. <i>Journal of Thoracic Oncology</i> , 2021, 16, 850-859.	0.5	35
53	Presymptomatic Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 Among Residents and Staff at a Skilled Nursing Facility: Results of Real-time Polymerase Chain Reaction and Serologic Testing. <i>Clinical Infectious Diseases</i> , 2021, 72, 686-689.	2.9	34
54	Allelic ratio of <i>KRAS</i> mutations in pancreatic ductal adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 4023-4023.	0.8	32

#	ARTICLE	IF	CITATIONS
55	Tumour budding, poorly differentiated clusters, and T-cell response in colorectal cancer. <i>EBioMedicine</i> , 2020, 57, 102860.	2.7	31
56	Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 123-132.	1.5	30
57	In chordoma, metastasis, recurrences, Ki-67 index, and a matrix-poor phenotype are associated with patients' shorter overall survival. <i>European Spine Journal</i> , 2016, 25, 4016-4024.	1.0	28
58	Novel and established EWSR1 gene fusions and associations identified by next-generation sequencing and fluorescence in-situ hybridization. <i>Human Pathology</i> , 2019, 93, 65-73.	1.1	27
59	Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. <i>Cancers</i> , 2019, 11, 2033.	1.7	26
60	Suppressor of cytokine signaling 1 gene mutation status as a prognostic biomarker in classical Hodgkin lymphoma. <i>Oncotarget</i> , 2015, 6, 29097-29110.	0.8	26
61	Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. <i>Neuro-Oncology</i> , 2019, 21, 596-605.	0.6	25
62	Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma. <i>Thyroid</i> , 2020, 30, 1384-1389.	2.4	25
63	Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion. <i>Journal of Thoracic Oncology</i> , 2019, 14, e226-e228.	0.5	24
64	Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms. <i>Human Pathology</i> , 2019, 86, 1-11.	1.1	24
65	Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1-KMT2A and VIM-KMT2A fusions. <i>Modern Pathology</i> , 2020, 33, 2307-2317.	2.9	24
66	Colorectal cancer in Crohn's colitis is comparable to sporadic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2016, 31, 973-982.	1.0	23
67	Osteoblast-Specific Krm2 Overexpression and Lrp5 Deficiency Have Different Effects on Fracture Healing in Mice. <i>PLoS ONE</i> , 2014, 9, e103250.	1.1	21
68	Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, 153-159.e3.	1.1	20
69	Targeted Informatics for Optimal Detection, Characterization, and Quantification of FLT3 Internal Tandem Duplications Across Multiple Next-Generation Sequencing Platforms. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1162-1178.	1.2	20
70	Clinical and Imaging Features of Non-Small Cell Lung Cancer with G12C KRAS Mutation. <i>Cancers</i> , 2021, 13, 3572.	1.7	19
71	A Regulatory Science Initiative to Harmonize and Standardize Digital Pathology and Machine Learning Processes to Speed up Clinical Innovation to Patients. <i>Journal of Pathology Informatics</i> , 2020, 11, 22.	0.8	19
72	Development of oil-based gels as versatile drug delivery systems for pediatric applications. <i>Science Advances</i> , 2022, 8, .	4.7	19

#	ARTICLE	IF	CITATIONS
73	Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma. <i>Oncologist</i> , 2019, 24, 1356-1367.	1.9	18
74	Immune cell profiles in the tumor microenvironment of early-onset, intermediate-onset, and later-onset colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 933-942.	2.0	18
75	Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-13.	1.5	17
76	Heparin-Coated Albumin Nanoparticles for Drug Combination in Targeting Inflamed Intestine. <i>Advanced Healthcare Materials</i> , 2020, 9, e2000536.	3.9	17
77	Resistance to lorlatinib in <i>ROS1</i> fusion-positive non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 9611-9611.	0.8	17
78	Enrichment of <i>HER2</i> Amplification in Brain Metastases from Primary Gastrointestinal Malignancies. <i>Oncologist</i> , 2019, 24, 193-201.	1.9	16
79	Health Care Infrastructure for Financially Sustainable Clinical Genomics. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 697-706.	1.2	15
80	Clinical Validation of a Cell-Free DNA Gene Panel. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 632-645.	1.2	15
81	Highly Multiplexed Fluorescence in Situ Hybridization for in Situ Genomics. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 390-407.	1.2	15
82	Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck. <i>Head and Neck</i> , 2016, 38, 1008-1016.	0.9	14
83	Artificial Intelligence Approach for Variant Reporting. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-13.	1.0	13
84	A rapid genotyping panel for detection of primary central nervous system lymphoma. <i>Blood</i> , 2021, 138, 382-386.	0.6	13
85	Ultra-rapid drug delivery in the oral cavity using ultrasound. <i>Journal of Controlled Release</i> , 2019, 304, 1-6.	4.8	12
86	Identification of Somatic Acquired <i>BRCA1/2</i> Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4852-4862.	3.2	12
87	Amyloid precursor protein-fragments-containing inclusions in cardiomyocytes with basophilic degeneration and its association with cerebral amyloid angiopathy and myocardial fibrosis. <i>Scientific Reports</i> , 2018, 8, 16594.	1.6	11
88	National Maintenance Cost for Precision Diagnostics Under the Verifying Accurate Leading-Edge In Vitro Clinical Test Development (VALID) Act of 2020. <i>JCO Oncology Practice</i> , 2021, 17, e1763-e1773.	1.4	11
89	Laboratory-Developed Tests in the New European Union 2017/746 Regulation: Opportunities and Risks. <i>Clinical Chemistry</i> , 2021, 68, 40-42.	1.5	11
90	Next-generation sequencing in the evaluation of biliary strictures in patients with primary sclerosing cholangitis. <i>Cancer Cytopathology</i> , 2022, 130, 215-230.	1.4	11

#	ARTICLE	IF	CITATIONS
91	Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3404-3413.	3.2	10
92	Remote Fingerstick Blood Collection for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Testing. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 415-418.	1.2	10
93	Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape. <i>JCO Precision Oncology</i> , 2022, , .	1.5	10
94	<i>KIF13B-NRG1</i> Gene Fusion and <i>KRAS</i> Amplification in a Case of Natural Progression of Lung Cancer. <i>International Journal of Surgical Pathology</i> , 2017, 25, 238-240.	0.4	9
95	Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2017, 12, e155-e157.	0.5	9
96	Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients With Minimal Smoking History. <i>Journal of Thoracic Oncology</i> , 2019, 14, 835-843.	0.5	9
97	Management of disseminated intravascular coagulation in a patient with hepatic angiosarcoma. <i>Medicine (United States)</i> , 2018, 97, e13321.	0.4	8
98	Smoking Status at Diagnosis and Colorectal Cancer Prognosis According to Tumor Lymphocytic Reaction. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa040.	1.4	8
99	Locally Recurrent Secretory Carcinoma of the Breast with <i>NTRK3</i> Gene Fusion. <i>Oncologist</i> , 2021, 26, 818-824.	1.9	8
100	Constitutively Active STAT6 Represses BCL6 in Primary Mediastinal B Cell Lymphoma.. <i>Blood</i> , 2012, 120, 2417-2417.	0.6	8
101	Implementing Keytruda/Pembrolizumab Testing in Clinical Practice. <i>Oncologist</i> , 2018, 23, 647-649.	1.9	7
102	The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA).. <i>Journal of Clinical Oncology</i> , 2020, 38, e16686-e16686.	0.8	7
103	Diagnostic Value of MAML2 Rearrangements in Mucoepidermoid Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4322.	1.8	7
104	Development of a qualitative real-time RT-PCR assay for the detection of SARS-CoV-2: a guide and case study in setting up an emergency-use, laboratory-developed molecular microbiological assay. <i>Journal of Clinical Pathology</i> , 2021, 74, 496-503.	1.0	5
105	t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity. <i>Blood Advances</i> , 2022, 6, 818-827.	2.5	5
106	Biopanel identifies expression status of targetable proteins in sinonasal melanoma. <i>Personalized Medicine</i> , 2016, 13, 291-301.	0.8	4
107	Role of imaging biomarkers in mutation-driven non-small cell lung cancer. <i>World Journal of Clinical Oncology</i> , 2020, 11, 412-427.	0.9	4
108	Clinical utility of a protein-based oncopanel in patients with end-stage head and neck cancer. <i>Immunotherapy</i> , 2019, 11, 1193-1203.	1.0	3

#	ARTICLE	IF	CITATIONS
109	PAX8-positive Biphasic Synovial Sarcoma Expressing Hormonal Receptors. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, e71-e74.	0.6	3
110	<i>MET</i> D1228N and D1246N are the Same Resistance Mutation in <i>MET</i> Exon 14 Skipping. Oncologist, 2021, 26, e2297-e2301.	1.9	3
111	Aneurysmal bone cyst with an unusual clinical presentation and a novel <i>VDR</i> – <i>USP6</i> fusion. Genes Chromosomes and Cancer, 2021, 60, 833-836.	1.5	3
112	Temporary Regulatory Deviations and the Coronavirus Disease 2019 (COVID-19) PCR Labeling Update Study Indicate What Laboratory-Developed Test Regulation by the US Food and Drug Administration (FDA) Could Look Like. Journal of Molecular Diagnostics, 2021, 23, 1207-1217.	1.2	3
113	Detecting predictive androgen receptor modifications in circulating prostate cancer cells.. Journal of Clinical Oncology, 2015, 33, 5067-5067.	0.8	3
114	Case 35-2016. New England Journal of Medicine, 2016, 375, 1983-1991.	13.9	2
115	MET Amplification in Esophageal Squamous Carcinoma. International Journal of Surgical Pathology, 2018, 26, 731-732.	0.4	2
116	Personalized Diagnostic Workflows: The Next Wave of Precision Medicine in NSCLC. Journal of Thoracic Oncology, 2020, 15, 888-890.	0.5	2
117	Observed progression from melanosis with melanocyte hyperplasia to sinonasal melanoma with distant metastasis and a unique genetic rearrangement. Journal of Cutaneous Pathology, 2021, 48, 948-953.	0.7	2
118	Do not sell regulatory science short. Nature Medicine, 2021, 27, 573-574.	15.2	2
119	Long-term efficacy and outcomes with sequential crizotinib followed by alectinib in ALK+ NSCLC.. Journal of Clinical Oncology, 2018, 36, 9093-9093.	0.8	2
120	Case 10-2017 “ A 6-Month-Old Boy with Gastrointestinal Bleeding and Abdominal Pain. New England Journal of Medicine, 2017, 376, 1269-1277.	13.9	1
121	Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: Differences between peripheral and central CGRP receptor distribution. Journal of Comparative Neurology, 2008, 507, spc1-spc1.	0.9	0
122	Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: Differences between peripheral and central CGRP receptor distribution. Journal of Comparative Neurology, 2008, 507, spc1-spc1.	0.9	0
123	Massive hepatomegaly and involvement by Janus kinase 2-positive myeloproliferative neoplasm. Hepatology, 2010, 52, 1855-1856.	3.6	0
124	Ring Around the Roses. International Journal of Surgical Pathology, 2011, 19, 194-195.	0.4	0
125	HCP-12IMPROVING THE EFFICIENCY OF MOLECULAR TESTING FOR EXPEDITED BRAIN TUMOR PATIENT MANAGEMENT AND CLINICAL TRIAL ENROLLMENT. Neuro-Oncology, 2015, 17, v103.4-v104.	0.6	0
126	<i>Silencer of Cytokine Signaling 1</i> gene is not hypermethylated in diffuse large B-cell lymphoma. British Journal of Haematology, 2017, 179, 158-160.	1.2	0



#	ARTICLE	IF	CITATIONS
127	Two In Cis Variantsâ€™Two Worlds Apart. <i>Oncologist</i> , 2021, 26, 997-999.	1.9	0
128	SOCS1 Mutation Subtypes Predict Divergent Outcomes in DLBCL Patients. <i>Blood</i> , 2012, 120, 419-419.	0.6	0
129	Absence Of BRAF and KRAS Hotspot Mutations In Primary Mediastinal and Other Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2013, 122, 4325-4325.	0.6	0
130	AST/GOT1 expression status in primary resection specimen as a prognostic biomarker in human pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2014, 32, e15245-e15245.	0.8	0
131	Clinical characteristics and treatment outcomes of patients with metastatic, MET-amplified esophagogastric cancers.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4043-4043.	0.8	0
132	BRAF-mutant non-small cell lung cancer (NSCLC): Patient (pt) characteristics and outcomes by class of mutation.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9045-9045.	0.8	0
133	Frequency and feasibility of detecting FGFR mRNA expression in archival samples of patients with cholangiocarcinoma (CCA).. <i>Journal of Clinical Oncology</i> , 2019, 37, 281-281.	0.8	0
134	An artificial intelligence approach to variant calling of ALK resistance mutations.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3079-3079.	0.8	0
135	The validity of VALID act: Cost modeling cancer diagnostics regulation by the FDA.. <i>Journal of Clinical Oncology</i> , 2020, 38, e14124-e14124.	0.8	0
136	BIOM-54. A RAPID GENOTYPING PANEL FOR SENSITIVE AND SPECIFIC SEGREGATION OF CNS PATHOLOGIES. <i>Neuro-Oncology</i> , 2020, 22, ii13-ii13.	0.6	0
137	Abstract P3-09-11: Clinical characteristics associated with <i>BRCA1/2</i> mutations identified on routine tumor tissue genotyping in metastatic breast cancer. <i>Cancer Research</i> , 2022, 82, P3-09-11-P3-09-11.	0.4	0
138	Clinicopathologic characteristics and outcomes for patients with <i>KRAS</i> G12D-mutant non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2022, 40, e21024-e21024.	0.8	0
139	Abstract 5248: CDK4/6 inhibition (CDK4/6i) is effective in the real-world setting for hormone receptor-positive metastatic breast cancer (HR+ MBC) with <i>ESR1</i> mutations and fusions. <i>Cancer Research</i> , 2022, 82, 5248-5248.	0.4	0
140	Abstract 4100: Developmental deconvolution for classification of cancer origin. <i>Cancer Research</i> , 2022, 82, 4100-4100.	0.4	0